Cisplatin (cis-diamminedichloroplatinum(II)) has long been an important tool in treating many different types of cancers. However, it suffers from limitations such as high secondary toxicity and drug resistance. Alternative metallopharmaceuticals are being developed, and ruthenium compounds with metal-arene bonds have been found to demonstrate promising antitumour activity.
展开▼
